Background: In cancer, apoptosis relevant proteins—such as CaM kinase, Bcl-2 or P53, topoisomerase I,
cell migration feature and DNA/BSA—macromolecules represent significant targets for current chemotherapeutics.
Objective: We recently reported two coordination compounds—[Cu(C6H16N2O2)2][Ni(CN)4] (1) and [Cu(C6H16
N2O2)Pd(CN)4] (2)—together with their IR spectra, magnetic properties, thermal analyses and crystal structures.
Herein, we describe the ability of these complexes to induce apoptosis in relevant proteins and stimulate
topoisomerase I activity, cell migration velocity and DNA/BSA binding properties.
Method: The in vitro antiproliferative effects and cell toxicity of both compounds were investigated through
pharmacological measurement techniques, and interactions between both compounds and CT-DNA/BSA were
studied with UV-Vis spectroscopy and fluorescence spectroscopy.
Results & Conclusion: Studies on cells revealed that 2 (i) demonstrated a high antiproliferative effect, which was
higher toward HeLa and C6 cancer cells than toward healthy Vero cells; (ii) impaired the migration of HeLa cells;
(iii) altered the P53-Bcl-2 ratio in favor of apoptosis; (iv) strongly bound to DNA/BSA macromolecules; and (v)
inhibited human topoisomerase I and KpnI or BamHI restriction endonucleases. In conclusion, this preliminary
information demonstrates that 2 may represent a promising antiproliferative agent and a potential candidate for a
therapeutic approach against HeLa.